Opicinumab
Opicinumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 3 | 2 | — | — | — | 5 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | 1 | — | — | — | — | 1 | |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OPICINUMAB |
| INN | opicinumab |
| Description | Opicinumab (BIIB033) is a fully human monoclonal antibody designed for the treatment of multiple sclerosis, acute optic neuritis (AON), and other associated demyelinating diseases. A biologic drug, it is designed to function as a LINGO-1 protein antagonist, known as “Anti-Lingo-1”.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1422268-07-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3544922 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14959 |
| UNII ID | WX1WTN0Y15 (ChemIDplus, GSRS) |
Target
Agency Approved
LINGO1
LINGO1
Organism
Homo sapiens
Gene name
LINGO1
Gene synonyms
LERN1, LRRN6A
NCBI Gene ID
Protein name
leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1
Protein synonyms
leucine rich repeat neuronal 6A, Leucine-rich repeat and immunoglobulin domain-containing protein 1, Leucine-rich repeat neuronal protein 1, Leucine-rich repeat neuronal protein 6A
Uniprot ID
Mouse ortholog
Lingo1 (235402)
leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 (Q9D1T0)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 171 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more